CHF stands for congestive heart failure, a condition where the heart can no longer pump blood efficiently enough to meet the body’s needs. Blood backs up in the system, causing fluid to build up in the lungs, legs, and other tissues. The American College of Cardiology and American Heart Association define it as a clinical syndrome resulting from any structural or functional impairment of the heart’s ability to fill with or eject blood.
How CHF Develops in the Body
Heart failure is a progressive disease, not a single event. It typically starts with some form of damage to the heart muscle: a heart attack, long-standing high blood pressure, a faulty valve, a viral infection of the heart, or even a genetic condition. Once that damage occurs, the heart tries to compensate. It may enlarge, pump faster, or trigger hormonal signals to retain fluid and constrict blood vessels in an attempt to maintain blood pressure.
These compensatory mechanisms work for a while, sometimes years. But eventually they backfire. The enlarged heart becomes weaker. The extra fluid that was supposed to help maintain blood pressure starts pooling where it shouldn’t. When heart muscle cells die or stop working properly, the heart can’t empty fully with each beat. The leftover blood raises pressure inside the heart, which pushes fluid backward into the lungs and, eventually, into the rest of the body.
Why Fluid Builds Up
The “congestive” in CHF refers to this fluid congestion, and it involves a chain reaction between the heart and kidneys. When the heart pumps less blood, the kidneys receive less blood flow. The kidneys interpret this as a signal that the body needs more fluid, so they retain sodium and water. The body also activates stress hormones that constrict blood vessels and further increase fluid retention.
This creates a vicious cycle: more fluid means more work for an already struggling heart, which means even less effective pumping, which triggers even more fluid retention. The result is swelling in the legs and ankles (peripheral edema), fluid in the lungs that causes shortness of breath, and sometimes fluid accumulation in the abdomen.
Left-Sided vs. Right-Sided Failure
CHF can affect the left side of the heart, the right side, or both. Left-sided heart failure is more common and affects the left ventricle, the chamber responsible for pumping oxygen-rich blood out to the body. When it fails, fluid backs up into the lungs. The hallmark symptom is shortness of breath, especially when lying flat or during physical activity.
Right-sided heart failure affects the chamber that receives blood returning from the body and pumps it to the lungs. When this side fails, blood backs up into the veins, causing swelling in the legs, ankles, feet, and sometimes the abdomen and liver. Right-sided failure often develops as a consequence of left-sided failure, since increased pressure in the lungs eventually strains the right side too.
Types Based on Pumping Strength
Doctors classify CHF by how well the left ventricle still pumps, measured as the “ejection fraction,” the percentage of blood pushed out with each heartbeat. A normal ejection fraction is roughly 55% to 70%.
- Heart failure with reduced ejection fraction (HFrEF): Ejection fraction of 40% or below. The heart muscle is weak and can’t contract forcefully enough. This is sometimes called systolic heart failure.
- Heart failure with mildly reduced ejection fraction (HFmrEF): Ejection fraction between 41% and 49%. A borderline category where the heart is impaired but not severely weakened.
- Heart failure with preserved ejection fraction (HFpEF): Ejection fraction of 50% or higher. The heart squeezes normally but is stiff and doesn’t relax or fill properly between beats. This type is more common in older adults, women, and people with high blood pressure or obesity.
The distinction matters because these types respond differently to treatment and progress differently over time.
Stages of Heart Failure
The 2022 AHA/ACC guidelines describe heart failure as a continuum with four stages, starting before symptoms ever appear.
Stage A is “at risk.” You have no heart damage and no symptoms, but you carry risk factors like high blood pressure, diabetes, obesity, metabolic syndrome, or a family history of cardiomyopathy. Stage B is “pre-heart failure,” where there’s evidence of structural heart changes or elevated biomarkers in your blood, but still no symptoms. Stages C and D are where active, symptomatic heart failure lives, with Stage D representing advanced disease that doesn’t respond to standard treatment.
This staging system was designed to emphasize prevention. Identifying people at Stages A and B and managing their risk factors can slow or prevent progression to symptomatic heart failure.
How Symptoms Are Graded
Once someone has symptomatic CHF, the New York Heart Association (NYHA) system grades how much daily life is affected:
- Class I: No limitation. Ordinary physical activity doesn’t cause fatigue, shortness of breath, or palpitations.
- Class II: Slight limitation. You’re comfortable at rest, but everyday activities like climbing stairs or carrying groceries cause fatigue or breathlessness.
- Class III: Marked limitation. Even light activity like walking across a room can trigger symptoms, though rest still brings relief.
- Class IV: Symptoms at rest. Any physical activity makes them worse.
Unlike the stages above, NYHA class can fluctuate. Someone at Class III during a flare-up might improve to Class II with treatment adjustments.
How CHF Is Diagnosed
Beyond physical examination and imaging like echocardiography (an ultrasound of the heart), blood tests play a key role. Two proteins released by stressed heart muscle, called BNP and NT-proBNP, help confirm or rule out heart failure. In a non-emergency setting, BNP levels above 35 pg/mL or NT-proBNP above 125 pg/mL warrant further investigation.
In an emergency, if BNP is below 100 pg/mL, heart failure is considered unlikely. Levels above 500 pg/mL strongly suggest heart failure is present. For NT-proBNP, levels below 300 pg/mL generally rule out acute heart failure, while the threshold for confirming it rises with age: above 450 pg/mL for people under 50, above 900 for those 50 to 75, and above 1,800 for people over 75.
Common Causes
Coronary artery disease, where the arteries supplying the heart muscle become narrowed or blocked, is the most common cause of CHF. A heart attack kills part of the heart muscle, leaving scar tissue that can’t pump. High blood pressure is the other major driver. It forces the heart to work harder for years, eventually thickening and stiffening the walls.
Other causes include damaged heart valves, viral infections that inflame the heart muscle (myocarditis), genetic conditions that weaken the heart, long-term alcohol abuse, certain chemotherapy drugs, and chronic conditions like diabetes and obesity that strain the cardiovascular system over time.
How CHF Is Managed
Treatment focuses on slowing disease progression, reducing fluid overload, and helping the heart work more efficiently. For people with reduced ejection fraction, a class of medications originally developed for diabetes (SGLT2 inhibitors) has become a cornerstone of treatment. Major guidelines now recommend these drugs across the full spectrum of ejection fractions, not just for reduced pumping strength. Studies show their benefits appear early but decline rapidly if the medication is stopped, so consistent use matters.
The broader treatment picture typically includes medications that reduce excess fluid, lower the workload on the heart, and block the harmful stress hormones that drive the vicious cycle of fluid retention. Lifestyle changes like limiting sodium intake, monitoring daily weight to catch fluid buildup early, and staying as physically active as symptoms allow are standard parts of management. For advanced cases, implanted devices that help regulate heart rhythm or assist with pumping, and in some cases heart transplantation, become options.
CHF is not curable in most cases, but many people live years or even decades with it when the condition is caught early and managed consistently. The key is recognizing that it’s a progressive disease, meaning ongoing treatment and monitoring aren’t optional but essential to maintaining quality of life.